Humacyte News and Activities
Presence
Humacyte develops regenerative medicine products for vascular repair. Its main offerings are bioengineered human tissue vessels and related implant services for hospitals, surgeons, and patients needing trauma repair, dialysis access, or other blood vessel treatment.
Humacyte products and services overview:
- Tissue engineered vessels
- Vascular grafts
- Regenerative medicine
- Biologic implants
Revenue: ~$10 million
Employees: 225
Headquarters: Durham, United States (USA)
Humacyte is a company listed under the stock ticker HUMA (US).
Acquisition, funding and merger involving Humacyte.
- Humacyte has just announced a $50 Million fundraising (posted on June 12 2026).
Executives
View the org chart displaying its 32 main executives
Most searched biographies at Humacyte
- Laura Niklason, Director, President and Chief Executive Officer
- Todd Pope, Director
- Bruce Green, Member of the Board
Popular executive movements at Humacyte
- Todd Rasmussen has joined the company as Chief Surgical Officer (posted on May 12 2026).
- BJ Scheessele, Chief Commercial Officer, has left the company (posted on April 22 2026).
- Jim Mercadante has joined the company as Chief Commercial Officer (posted on April 22 2026).
Click here to view some more movements at Humacyte
Create your alert
to follow the executive moves at Humacyte.
Biotechnology
Humacyte has 2,428 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Eli Lilly has announced the acquisition of AtaiBeckley (posted on July 17 2026).
- GSK has acquired Nuvalent (posted on July 17 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (posted on July 15 2026).
Popular contacts in Biotechnology
News
Press releases by Humacyte
- Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting | Humacyte, Inc.
- Humacyte, Inc. Announces Pricing of Public Offering of Common Stock | Humacyte, Inc.
- Humacyte, Inc. Announces Proposed Public Offering of Common Stock | Humacyte, Inc.
- Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients | Humacyte, Inc.
- Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access | Humacyte, Inc.
- Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs | Humacyte, Inc.
- Press Releases | Humacyte, Inc.
- Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026 | Humacyte, Inc.
- Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess® | Humacyte, Inc.
- Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 | Humacyte, Inc.
- View more press releases Close
Social media about Humacyte
- Humacyte on Wikipedia, Google News & Yahoo Finance
- Humacyte on LinkedIn, X (Twitter) & YouTube
